Communique of GTTAC Meeting of 14 April 2016
This Communiqué covers matters considered at the 11th video conference of the Gene Technology Technical Advisory Committee (14 April 2016).
IDT Australia is seeking approval to conduct a Phase I/IIa clinical trial using GM Sendai virus to treat leg pain in individuals with peripheral artery disease. The GMO produces human fibroblast growth factor 2 (hFGF-2), which is anticipated to stimulate the growth of new blood vessels and in doing so, ease the pain. The proposed study would be conducted at a single clinical site in Adelaide, SA, and would involve eighteen trial participants.